Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer

This publication has 20 references indexed in Scilit:

• In Reply:
  Journal of Clinical Oncology, 2006
• An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial
  Annals of Oncology, 2005
• Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
  New England Journal of Medicine, 2005
• A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis
  Annals of Oncology, 2005
• Are Patients Diagnosed With Breast Cancer Before Age 50 Years Ever Cured?
  Journal of Clinical Oncology, 2004
• Do Estimates of Long-Term Survival Tell Us Whether Patients Diagnosed With Breast Cancer Before Age 50 Years Are Ever Cured?
  Journal of Clinical Oncology, 2004
• Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5‐fluorouracil, vincristine, and prednisone compared with single‐agent L‐phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes
  Cancer, 2002
• Factors influencing the effect of age on prognosis in breast cancer: population based study Commentary: much still to learn about relations between tumour biology, prognosis, and treatment outcome in early breast cancer
  BMJ, 2000
• Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up
  New England Journal of Medicine, 1995
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987